← Back to Clinical Trials
Recruiting NCT06896240

NCT06896240 Fiber Smoothie Supplement

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06896240
Status Recruiting
Phase
Sponsor Hospital for Special Surgery, New York
Condition Total Knee Arthroplasty Revision
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2026-04-28
Primary Completion 2027-01-01

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Assigned Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 24 participants in total. It began in 2026-04-28 with a primary completion date of 2027-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to assess the feasibility of a 2-week dietary whole-food smoothie intervention and compare outcomes between two groups: patients that integrated a daily whole food plant-based smoothie into their diet for two weeks prior to surgery, and a control group of revision TKA patients that made no nutritional changes to their diet prior to surgery. The main research questions are: 1. Among patients planned for elective TKA revision surgery, what is the feasibility of a 2-week dietary intervention implemented 2 weeks prior to surgery? \[Outcomes will be compliance, noted barriers and/or facilitators, satisfaction with diet\] 2. Determine if the implementation of a daily whole food plant- based smoothie dietary supplement 2 weeks prior to TKA revision surgery will reduce inflammation -measured in plasma levels of IL-6 and CRP- at POD0, POD1, POD2, POD3, and 6 Weeks Post-operative as compared to 1) baseline (prior to dietary intervention initiation) and 2) control patients who did not make changes in their diet prior to surgery. 3. Determine if the implementation of a daily whole food plant-based smoothie dietary supplement 2 weeks prior to TKA revision surgery will result in quantifiable changes in the gut microbiome composition -measured via fecal samples- as compared to control patients who did not make changes in their diet prior to surgery. 4. Determine if the implementation of a daily whole food plant- based smoothie dietary supplement 2 weeks prior to TKA revision surgery will result in improved immediate postoperative pain -measured through numeric rating scale (NRS) pain scores- and opioid use -measured in morphine milligram equivalents (MME)- as compared to control patients. 5. Compare patient satisfaction and adoption of nutritional behavioral changes in patients implementing a whole food plant-based smoothie 2 weeks prior to TKA revision surgery to patients undergoing the same surgery but did not me pre-surgery dietary changes. The researcher's primary outcome is measuring feasibility and patient compliance with smoothie consumption. Secondarily, the investigators are interested in measuring if the preoperative smoothie can alter the gut microbiome and decrease systemic inflammation, leading to lowered post-operative pain and opioid use.

Eligibility Criteria

Inclusion: * Scheduled for revision TKA at HSS with participating surgeons; not as a result of infection or trauma and all components (tibial and femoral) needing replacement * Age between 40 and 80 * Diagnosed with osteoarthritis * Diagnosed with 2+ modifiable chronic lifestyle diseases: Type 2 DM, CVD (such as CAD, heart disease, stroke, HTN), stress, anxiety, depression, ADHD, metabolic syndrome, certain types of cancer (such as breast, colorectal, lung, prostate), Alzheimer's disease, vascular cognitive impairment, CKD, RA, asthma, chronic pain conditions (such as chronic back pain and osteoarthritis), fibromyalgia, migraines, COPD (Steiber 2011, Grant 2014) * ASA Class 1 ('normal' healthy patient) or 2 (patient with mild systemic disease and no functional limitations; the diseases the patient has are well controlled) * Ability to understand written and spoken English * Willing to complete entire pre-operative and post-operative work up in NYC, main campus site * Willing to follow a 2-week smoothie supplement, including willingness to purchase ingredients and have access to a blender for preparation Exclusion: * Age \>80 years or \<40 years * Revision due to infection or trauma * ASA class 3 (patient with severe systemic disease that results in functional limitations) or 4 (patient with severe systemic disease that is a constant threat to life) * Not interested or unable to provide informed consent * Unstable weight (\>5kg weight change in the past 3 months, documented in Epic) or currently on weight loss drugs such as GLP-1 agonists (Prasad et al., Cardiovasc Diabetol 2022; empagliflozin CRP studies.) * Active infection, flare-up of seasonal allergies, or physical trauma (all can alter CRP) * Medication changes the month leading up to surgery * Specifically medications altering inflammation: Statins (Ridker 2008), steroids (Boumpas et al., Ann Intern Med 1993; glucocorticoid cytokine modulation research.), DMARDS/biologics/immunosuppressants (Clinical rheumatology guidelines, biologic RCTs (e.g., TNF inhibitors, IL-6 inhibitors), Colchicine (Tardif et al., N Engl J Med 2019; colchicine cardiovascular inflammation studies.), hormone replacement therapies (Ridker et al., JAMA 1999; OCs and CRP meta-analyses.), new psychiatric medications (Miller \& Raison, Nat Rev Immunol 2016; psychotropic-inflammation associations.) * BMI \>40 kg/m2 * Food intolerance/allergy/sensitivity to ingredients suggested for smoothies * History of IBD (and IBD medication) * History of bariatric surgery * History of cancer * History of thyroid disease * History of or current drug abuse * Pregnancy * Current smoker * Any patient with an electronic cardiac implant

Contact & Investigator

Central Contact

Mia Zonies, BS

✉ zoniesm@hss.edu

📞 646-714-6849

Principal Investigator

Erica Tafuro, MD

PRINCIPAL INVESTIGATOR

Hospital for Special Surgery, New York

Frequently Asked Questions

Who can join the NCT06896240 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Total Knee Arthroplasty Revision. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06896240 currently recruiting?

Yes, NCT06896240 is actively recruiting participants. Contact the research team at zoniesm@hss.edu for enrollment information.

Where is the NCT06896240 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT06896240 clinical trial?

NCT06896240 is sponsored by Hospital for Special Surgery, New York. The principal investigator is Erica Tafuro, MD at Hospital for Special Surgery, New York. The trial plans to enroll 24 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology